TY - CHAP M1 - Book, Section TI - Diffuse Large B-Cell Lymphoma and Related Neoplasms A1 - Smith, Stephen D. A1 - Press, Oliver W. A2 - Press, Oliver W. A2 - Lichtman, Marshall A. A2 - Leonard, John P. PY - 2017 T2 - Williams Hematology Malignant Lymphoid Diseases AB - SUMMARYDiffuse large B-cell lymphomas (DLBCLs) comprise a heterogeneous group of aggressive malignancies of large, transformed B lymphocytes. DLBCL is the most common lymphoma in the world and accounts for approximately 25 to 30 percent of lymphoma cases in the United States. The incidence increases with age, with a median age at presentation in the sixth decade. The disease typically presents as a rapidly growing mass that may involve either lymph node or extranodal sites and often is associated with systemic symptoms. Approximately 50 to 60 percent of patients will present with advanced-stage, disseminated disease. DLBCL is curable with combination chemotherapy. For localized disease, either three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus involved-field radiation therapy or six cycles of (R-CHOP) are recommended, whereas for advanced-stage DLBCL, six cycles of R-CHOP are appropriate. High-dose chemotherapy with autologous stem cell transplantation may be curative for patients with DLBCL that relapses after treatment with frontline chemotherapy. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1148368604 ER -